Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
Laufs U, Birkenfeld AL, Fraass U, Hohenstein B, Siegert C, Klotsche J, Steinhagen-Thiessen E, Pittrow D, Dexl S, Salmen S, Schettler VJJ, Parhofer KG; Collaborators in the PERI-DYS Study. Laufs U, et al. Among authors: parhofer kg. Cardiovasc Drugs Ther. 2024 Feb;38(1):119-129. doi: 10.1007/s10557-022-07386-0. Epub 2022 Sep 30. Cardiovasc Drugs Ther. 2024. PMID: 36178485 Free PMC article.
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
Moriarty PM, Parhofer KG, Babirak SP, deGoma E, Duell PB, Hohenstein B, Ramlow W, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Moriarty PM, et al. Among authors: parhofer kg. J Clin Lipidol. 2016 May-Jun;10(3):627-34. doi: 10.1016/j.jacl.2016.02.003. Epub 2016 Feb 18. J Clin Lipidol. 2016. PMID: 27206951 Clinical Trial.
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Moriarty PM, et al. Among authors: parhofer kg. Eur Heart J. 2016 Dec 21;37(48):3588-3595. doi: 10.1093/eurheartj/ehw388. Epub 2016 Aug 29. Eur Heart J. 2016. PMID: 27572070 Free PMC article. Clinical Trial.
Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Koenig W, Otte B, Parhofer KG, Reinhard W, Schatz U, Schunkert H, Steinhagen-Thiessen E, Vogt A, Laufs U, März W. Schmidt N, et al. Among authors: parhofer kg. Atherosclerosis. 2018 Oct;277:314-322. doi: 10.1016/j.atherosclerosis.2018.08.050. Atherosclerosis. 2018. PMID: 30270065 Free article.
Clinical review on triglycerides.
Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Laufs U, et al. Among authors: parhofer kg. Eur Heart J. 2020 Jan 1;41(1):99-109c. doi: 10.1093/eurheartj/ehz785. Eur Heart J. 2020. PMID: 31764986 Free PMC article. Review.
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus.
Parhofer KG, Birkenfeld AL, Krone W, Lehrke M, Marx N, Merkel M, Schütt KS, Zirlik A, Müller-Wieland D. Parhofer KG, et al. Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S97-S101. doi: 10.1055/a-1018-9228. Epub 2019 Dec 20. Exp Clin Endocrinol Diabetes. 2019. PMID: 31860929 Free article. No abstract available.
The Diagnosis and Treatment of Hypertriglyceridemia.
Parhofer KG, Laufs U. Parhofer KG, et al. Dtsch Arztebl Int. 2019 Dec 6;116(49):825-832. doi: 10.3238/arztebl.2019.0825. Dtsch Arztebl Int. 2019. PMID: 31888796 Free PMC article. Review.
In Reply.
Parhofer KG, Laufs U. Parhofer KG, et al. Dtsch Arztebl Int. 2020 Mar 27;117(13):224. doi: 10.3238/arztebl.2020.0224b. Dtsch Arztebl Int. 2020. PMID: 32343667 Free PMC article. No abstract available.
353 results